ALRN Stock Overview
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States.
Aileron Therapeutics, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.23|
|52 Week High||US$1.27|
|52 Week Low||US$0.13|
|1 Month Change||2.15%|
|3 Month Change||-48.17%|
|1 Year Change||-78.29%|
|3 Year Change||-70.34%|
|5 Year Change||-98.10%|
|Change since IPO||-97.89%|
Recent News & Updates
Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|ALRN||US Biotechs||US Market|
Return vs Industry: ALRN underperformed the US Biotechs industry which returned -22.2% over the past year.
Return vs Market: ALRN underperformed the US Market which returned -8.9% over the past year.
|ALRN Average Weekly Movement||15.9%|
|Biotechs Industry Average Movement||12.3%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||17.0%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: ALRN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: ALRN's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC.
Aileron Therapeutics, Inc. Fundamentals Summary
|ALRN fundamental statistics|
Is ALRN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ALRN income statement (TTM)|
|Cost of Revenue||US$17.01m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.33|
|Net Profit Margin||0.00%|
How did ALRN perform over the long term?See historical performance and comparison